
Biogen (BIIB) Stock Forecast & Price Target
Biogen (BIIB) Analyst Ratings
Bulls say
Biogen is an established biopharmaceutical company that is making strategic moves to strengthen and diversify its portfolio, with recent acquisitions and ongoing development of potential treatments for rare diseases and neurodegenerative conditions. The company's strong financial discipline and success in the neuroscience field, along with potential commercial success of new therapies, make it a promising investment opportunity for those with a positive outlook on the stock.
Bears say
Biogen is facing significant challenges with its declining multiple sclerosis franchise and the recent setback for its Alzheimer's drug, lecanemab. Even with potential contributions from newer franchises, such as Spinraza and Skyclarys, Biogen's success may be limited due to increasing competition and uncertainty around product approvals. The company's financials may also be impacted by the CVR structure and potential generic competition for Tecfidera. Overall, Biogen may struggle to maintain its current revenue levels and profitability, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares